Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 25, 2026

BLRM-EffTox: A seamless two-stage phase 1 Bayesian logistic regression design incorporating efficacy-toxicity trade-off for dose optimization.

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXin LiuCBCynthia BasuAMArnab Kumar Maity

Discussion

Loading...

Member takes

Overview

Novel design optimizes dose considering efficacy and toxicity in phase 1 oncology trials, suggesting improved outcomes.

Key Points

  • The research aims to develop a two-stage Bayesian design for optimizing doses in oncology trials, balancing efficacy and toxicity.
  • Proposed a seamless two-stage design, BLRM-EffTox, to model both toxicity and efficacy.
  • Used a decision index to select and randomize multiple doses during trials.
  • Compared the design to existing methods including BLRM-MTD and BLRM-Eff2d using simulations.
  • Simulations indicate that BLRM-EffTox outperforms traditional dose-finding designs.
  • Increased efficiency in identifying optimal doses while managing toxicity.
  • Demonstrated practical application through two case studies.

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/699e912ef5123be5ed04e7f3https://doi.org/10.1080/10543406.2026.2627385
View Full Paper
Ask AI
Bookmark
Share